Novartis

NOVN.SW Mega Cap

Healthcare · Drug Manufacturers - General

Updated: Apr 5, 2026, 00:03 UTC

CHF 123.20

+0.24% today

52W: CHF 81.10 – CHF 131.00

52W Low: CHF 81.10 Position: 84.4% 52W High: CHF 131.00

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

21.61x

Price-to-Earnings

Forward P/E

15.67x

Forward Price/Earnings

P/S Ratio

4.15x

Price-to-Sales

EV/EBITDA

11.05x

Enterprise Value/EBITDA

Div. Yield

300%

Annual dividend yield

Market Cap

$235.1B

Market Capitalization

Revenue Growth

2.2%

YoY Revenue Growth

Profit Margin

24.67%

Net profit margin

ROE

30.81%

Return on Equity

Beta

0.52

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

3,385,636

Average daily volume

Valuation Analysis

Signal

Fair

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Hold

21 analysts

Avg. Price Target

CHF 123.13

-0.06% upside

Target Range

CHF 94.00 – CHF 143.48

🚫 Not currently held by any of our 15 tracked Smart Money managers. View Smart Money Tracker →

About the Company

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acu

Sector: Healthcare Industry: Drug Manufacturers - General Country: Switzerland Employees: 75,267 Exchange: EBS